A

Amgen

Biotech company creating biologic medicines

District Sales Manager

Full-TimeUpdated on 10/2/2026Deadline 10/30/26
$187.6k - $253.7k/yr
Mid, Senior
Bachelor's, Master's, PhD
Kansas City, KS, USA
RemoteApproximately 80% travel is required, including some overnight and weekend commitments.

About the job

Requirements
  • Doctorate degree and 2 years of Sales or Marketing experience, or Master's degree and 6 years of Sales or Marketing experience, or Bachelor's degree and 8 years of Sales or Marketing experience.
  • Two years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources.
  • Approximately 80% travel, including some overnight and weekend commitments.
  • Proficiency in Microsoft Office.
  • Experience in biologics, infusion, and/or rare or specialty products is preferred.
  • Rare disease experience and rare disease launch experience are preferred.
  • Immunology and/or Rheumatology experience is preferred.
  • Buy-and-bill experience is preferred.
  • Experience working with institutions and integrated delivery networks is preferred.
  • Ability to maintain a professional and proactive demeanor.
  • Strong interpersonal skills.
  • Excellent written and verbal communication skills.
Responsibilities
  • Lead the area geography and team of Specialty Account Managers to ensure market penetration by analyzing market dynamics and data, setting strategic action plans, and executing effectively to achieve sales goals within the Endocrinology space.
  • Provide a clear and compelling clinical and business sales purpose for team members.
  • Ensure effective and appropriate use of territory management tools and data, cross-functional partners, marketing tools, and other resources.
  • Build business strategy and strategic impact aligned with corporate and therapeutic-area goals.
  • Lead market development initiatives aligned with corporate and therapeutic-area goals.
  • Manage administrative duties, ongoing learning for self and team members, operational expenses, and program funding.
  • Ensure team members operate within regulatory guidelines for promotion, program implementation, and product compliance.
  • Ensure the team is trained and prepared to maximize business and sales potential and that product messaging is consistently delivered with impact.
  • Achieve organizational sales volume, target reach and frequency objectives, and other key performance indicators related to execution excellence.
  • Establish a productive work environment based on trust and respect within the national Endocrinology sales team and act as a business partner across the business unit.
  • Collaborate effectively across all divisions within the business unit to achieve business objectives.
  • Create opportunities to recognize and reward outstanding individual and team sales performance.
  • Build an organization that presents a highly professional workforce to external and internal partners.
  • Address performance issues decisively and appropriately.
  • Develop internal and external customer relationships to drive business objectives within the therapeutic area.
  • Foster the flow of insights and deliver influential messages that gain support for initiatives.
  • Develop and communicate professional growth plans for self and team members.
  • Continually educate self and the team on Endocrinology market issues, trends, and product knowledge relevant to business interests.
  • Apply innovative technologies to improve efficiency, expand the knowledge base, and refine skill building.
  • Conduct weekly ride-alongs with team members and provide written feedback and coaching.
  • Represent the organization at local, regional, and national trade shows.
  • Provide input to regional and national sales meetings, including content and objectives.
  • Maintain a safe working environment by preventing accidents, preserving equipment, and achieving safe working practices.
  • Adhere to Amgen policies and procedures and perform other assigned duties.
Desired Qualifications
  • Experience in biologics, infusion, and/or rare or specialty products.
  • Rare disease experience.
  • Rare disease launch experience.
  • Immunology and/or Rheumatology experience.
  • Buy-and-bill experience.
  • Experience working with institutions and integrated delivery networks.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
  • Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
  • Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.

What critics are saying

  • Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
  • Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
  • MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.

What makes Amgen unique

  • September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
  • August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
  • MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.